CD19 and myeloid sarcoma: In a cohort of 53 MS patients treated with OFA, CD20+ lymphocytes were completely depleted after the first administration in all but three patients; at the same time point, CD3+CD20+ T lymphocytes were completely depleted in all the patients, while CD19+CD20+ B lymphocytes could still be measured at a low level in three patients [18].